Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - lansoprazole - gastro-resistant capsule, hard - 30 milligram(s) - proton pump inhibitors; lansoprazole

Iisrael - inglise - Ministry of Health

rafa laboratories ltd - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - • treatment of duodenal and gastric ulcer• treatment of reflux oesophagitis• prophylaxis of reflux oesophagitis• eradication of helicobacter pylori (h. pylori) concurrently given with appropriate antibiotic therapy for treatment of h.pylori-associated ulcers• treatment of nsaid-associated benign gastric and duodenal ulcers in patients requiring continued nsaid treatment• prophylaxis of nsaid-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy• symptomatic gastroesophageal reflux disease• zollinger-ellison syndrome.

Iisrael - inglise - Ministry of Health

rafa laboratories ltd - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - lansoprazole - • treatment of duodenal and gastric ulcer• treatment of reflux oesophagitis• prophylaxis of reflux oesophagitis• eradication of helicobacter pylori (h. pylori) concurrently given with appropriate antibiotic therapy for treatment of h.pylori-associated ulcers• treatment of nsaid-associated benign gastric and duodenal ulcers in patients requiring continued nsaid treatment• prophylaxis of nsaid-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy• symptomatic gastroesophageal reflux disease• zollinger-ellison syndrome.

Iisrael - inglise - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Iisrael - inglise - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Iisrael - inglise - Ministry of Health

teva israel ltd - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - • treatment of duodenal and gastric ulcer • treatment of reflux oesophagitis• prophylaxis of reflux oesophagitis• eradication of helicobacter pylori (h. pylori) concurrently given with appropriate antibiotic therapy for treatment of h.pylori-associated ulcers• treatment of nsaid-associated benign gastric and duodenal ulcers in patients requiring continued nsaid treatment• prophylaxis of nsaid-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy• symptomatic gastroesophageal reflux disease• zollinger-ellison syndrome.

Iisrael - inglise - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Iisrael - inglise - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

imbat limited - lansoprazole - orodispersible tablet - 30 milligram - proton pump inhibitors

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

imbat limited - lansoprazole - orodispersible tablet - 15 milligram - proton pump inhibitors